| Diabetes Mellitus, Non-Insulin-Dependent

Cycloset vs Ozempic

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Cycloset vs Ozempic with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOzempic has a higher rate of injection site reactions vs Cycloset based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Ozempic but not Cycloset, including UnitedHealthcare

Category

Cycloset

Ozempic

At A Glance

RouteOral

FrequencyDaily

ClassDopamine D2 receptor agonist

RouteSC injection

FrequencyOnce weekly

ClassGLP-1 receptor agonist

Indications

Diabetes Mellitus, Non-Insulin-Dependent

Diabetes Mellitus, Non-Insulin-Dependent
Chronic Kidney Diseases

Dosing

Diabetes Mellitus, Non-Insulin-Dependent 1.6 mg to 4.8 mg once daily within 2 hours after waking in the morning with food; initiate at 0.8 mg, increase by one tablet per week to maximal tolerated dose; limit to 1.6 mg daily with moderate CYP3A4 inhibitors; avoid with strong CYP3A4 inhibitors.

Diabetes Mellitus, Non-Insulin-Dependent Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; escalate to 1 mg then 2 mg based on glycemic control (max 2 mg once weekly).

Chronic Kidney Diseases Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; maintenance dose is 1 mg once weekly.

Contraindications

Known hypersensitivity to bromocriptine, ergot-related drugs, or any excipient in CYCLOSET
Syncopal migraine
Postpartum patients
Lactating patients

Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
Serious hypersensitivity reaction to semaglutide or any excipient in Ozempic

Drug Interactions

1193View drug interactions

943View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, fatigue, vomiting, headache, dizziness, rhinitis, constipation, sinusitis, diarrhea, asthenia, somnolence, dyspepsia, amblyopia, anorexia

Serious Hypotension, psychotic disorders, somnolence, syncope, fibrotic-related complications, cardiovascular events (myocardial infarction, stroke)

Postmarketing Hallucinations, retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pericarditis, pericardial effusions, cardiac valvulopathy, psychotic and psychiatric disorders, impulse control/compulsive behaviors, neuroleptic-like malignant syndrome

Most common (>=5%) Nausea, vomiting, diarrhea, abdominal pain, constipation

Serious Risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration

Postmarketing Ileus, intestinal obstruction, severe constipation, fecal impaction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholecystectomy, dysesthesia, headache, pulmonary aspiration, acute kidney injury, alopecia

Pharmacology

CYCLOSET (bromocriptine mesylate) is a sympatholytic dopamine D2 receptor agonist; timed morning administration in type 2 diabetes is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia without raising plasma insulin levels.

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in gastric emptying; prolonged half-life is achieved through albumin binding, which reduces renal clearance and protects against metabolic degradation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cycloset